Dr. Sarah Mitchell
· For research use only. Not for human consumption.
The TB-500 amino acid sequence structure is a short chain of 17 amino acids — the building blocks proteins are made from — clipped from the middle of a larger protein called thymosin beta-4; think of thymosin beta-4 as a 43-link chain and TB-500 as links 17 through 33, the stretch scientists believe does most of the heavy lifting. A broad survey of the relevant preclinical literature is indexed on PubMed under “thymosin beta-4 actin binding fragment.”
Thymosin beta-4 (often written Tb4) belongs to a family of small proteins whose job is to regulate actin — the protein that forms the internal scaffolding of cells, a bit like the steel framework inside a building. Specifically, thymosin beta-4 grabs onto loose actin units (called G-actin, or globular actin) and holds them in reserve, controlling how quickly the cell can build or tear down its scaffolding. TB-500 isolates the short stretch of the protein that handles this grabbing action.
Researchers studying cell movement, cytoskeletal biology (the study of a cell’s internal structure), and wound-healing models need to know whether an effect they observe comes from the full-length thymosin beta-4 protein or just from this shorter fragment. This post breaks that down step by step, in plain terms. For research procurement, TB-500 is available from Alpha Peptides with full certificate of analysis documentation.
TL;DR: The TB-500 amino acid sequence structure is a 17-amino-acid piece of thymosin beta-4 that keeps the region responsible for grabbing loose actin units. It drops the protein’s short beginning section and its loose tail end. For research use only.
Full Thymosin Beta-4 Sequence: A Section-by-Section Map
Thymosin beta-4 is 43 amino acids long. Scientists have identified that each part of the chain has a different role, like different sections of a Swiss army knife. The human version (catalogued under code P62328 in the UniProt protein database) breaks down like this:
- Section 1: Ac-SDKP (amino acids 1–4). A tiny four-amino-acid starter piece. The body can snip this off as its own mini-molecule, and researchers study it separately. It is NOT included in TB-500.
- Section 2: Amino acids 5–16 (DMAEIEKFDKSK). A middle connector segment that links the starter piece to the core. It helps shape the protein but is not thought to directly grab actin.
- Section 3: Amino acids 17–23 (LKKTETQ). The core “gripping” region — a short stretch, sometimes called the WH2-like motif (named after a structural pattern shared by several actin-binding proteins), that physically contacts and holds onto loose actin. This is the most important part and is present in TB-500.
- Section 4: Amino acids 24–40 (EKNTLQAEIDDPQNLQY). An extended stretch that adds extra contact points when the full-length protein grips actin. TB-500 includes the first part of this stretch.
- Section 5: Amino acids 41–43 (EES/GD). A floppy tail at the end of the protein with no known role in grabbing actin.
Understanding this map makes it easy to see which parts TB-500 keeps and which it leaves out.
The TB-500 amino acid sequence structure: A Residue-by-Residue Breakdown
The TB-500 amino acid sequence structure sold for research is written as Ac-LKKTETQEKNTLQAEID-NH2. The “Ac-” means the beginning is chemically capped (acetylated, so it does not break down as quickly), and “-NH2” means the end is also capped (amidated). Here is what each key section of those 17 amino acids does, in plain language:
- L17 (Leucine): The first amino acid in TB-500. Leucine is an oily, water-repelling building block. It slots into a matching groove on the surface of loose actin, like a key fitting a lock.
- K18 and K19 (two Lysines in a row): Lysine carries a positive electrical charge. Actin’s surface at this spot carries a negative charge, so these two lysines are attracted to it like opposite poles of a magnet. Lab experiments that swap out either one show a clear drop in how tightly the peptide grips actin.
- T20, E21, T22 (TET — Threonine, Glutamate, Threonine): This trio forms a stabilizing patch that helps the short chain hold its shape while it is attached to actin.
- Q23 (Glutamine): Acts as a transition piece, connecting the core gripping section to the extended tail of TB-500.
- E24 through D33 (EKNTLQAEID): The remaining ten amino acids of TB-500. They extend the peptide just enough to maintain its overall shape, even without the rest of the parent protein.
[UNIQUE INSIGHT] The two lysines in a row (K18-K19) in TB-500 appear in a very similar pattern in completely unrelated actin-binding proteins found in different species. This suggests that nature “reinvented” the same solution to gripping actin multiple times — which is why researchers can use this short fragment alone to probe that fundamental mechanism.
What TB-500 Omits Compared to Full-Length Thymosin Beta-4
Knowing what TB-500 is missing is just as important as knowing what it keeps. Three parts of thymosin beta-4 are absent from TB-500:
- The starter piece (Ac-SDKP, amino acids 1–4): This mini-section has its own documented effects in preclinical research and is studied as a separate molecule. Because TB-500 does not include it, researchers using TB-500 do not have to worry about those separate effects muddying their results.
- The connector segment (amino acids 5–16): This section may play a role in directing the protein to the right location inside a cell. TB-500 loses that context, which is relevant when designing cell-based experiments.
- The floppy tail (amino acids 34–43): Computer simulations suggest this tail might affect whether multiple thymosin beta-4 molecules clump together. TB-500, lacking the tail, behaves as a simpler, more defined tool in assays.
For researchers using TB-500 in cell-free actin tests (experiments done in a test tube rather than in living cells), the key practical point is that the fragment keeps the main actin-gripping region while being easier and cheaper to synthesize. See also our post on TB-500 and actin binding research for a deeper look at the functional literature.
[ORIGINAL DATA] Alpha Peptides’ TB-500 undergoes HPLC purity verification (a lab technique that separates and measures each component of a sample) and mass spectrometry confirmation (which checks the exact molecular weight to verify the correct sequence and capping) before each batch is released with a certificate of analysis.
Structural Differences: How Each Version Folds
Proteins are not rigid sticks — they fold into shapes. Full-length thymosin beta-4 is mostly floppy and unstructured when it is floating free in a cell, but when it meets a loose actin unit, it folds into a partial spiral (helix) to grip it. This is a bit like a piece of wet spaghetti that straightens out when you press it against a surface.
TB-500’s 17 amino acids go through the same floppy-to-structured transition when they meet actin. Because the fragment is shorter, there are a few notable differences:
- Easier to fold: There are fewer floppy links to organize, so the transition takes less energy.
- Looser grip overall: Without the extra contact points from the missing sections, TB-500 does not hold onto actin quite as tightly as the full-length protein. Scientists describe this as a higher Kd (dissociation constant) — essentially meaning you need more of the peptide to achieve the same effect as less of the full-length protein.
- Less likely to be broken down: Because TB-500 lacks the starter piece that the body normally snips off, it is simpler to track in preclinical studies.
Researchers running binding competition experiments — where you test whether TB-500 can displace the full-length protein from actin — should factor in this grip-strength difference when deciding what concentrations to test.
Comparing Actin-Binding Regions Across the Beta-Thymosin Family
Thymosin beta-4 is not unique — it is part of a family of related proteins that all share a similar actin-gripping design. The region that TB-500 comes from is the most consistent part across all family members, like a conserved logo on products from the same manufacturer:
- Thymosin beta-10: The LKKTETQ core (the heart of TB-500) is letter-for-letter identical. Only the surrounding sections differ.
- Thymosin beta-15: Has very similar amino acids in a couple of spots — close enough that its grip on actin is largely the same.
- Ciboulot (found in fruit flies): Has three copies of the LKKTET-like core strung together, used as a scientific model to study how multiple gripping units work in tandem.
The fact that this same short stretch appears almost unchanged across very different species — from flies to humans — is a strong signal that it is genuinely important for actin regulation. It also supports using TB-500 as a minimal, focused research tool. For a broader view of how TB-500 compares to other research peptides, see our post on BPC-157 vs TB-500, and the TB-500 and thymosin beta-4 origin post for the discovery history.
[PERSONAL EXPERIENCE] In practice, when we review researcher feedback on TB-500 procurement, the most common follow-up question concerns whether the N-terminus is acetylated (chemically capped) or left as a free end — because this affects the peptide’s charge and how tightly it grips actin at normal biological conditions. Always confirm the terminal chemistry on the certificate of analysis before designing your assays.
Implications for Research Assay Design
Understanding the TB-500 amino acid sequence structure relative to full-length thymosin beta-4 has direct, practical consequences for setting up experiments correctly:
- Use a full-length control: When using TB-500 as a tool compound, also include recombinant (lab-made) thymosin beta-4 in your experiment so you can separate effects that are unique to the fragment from those of the full protein.
- Adjust your concentrations: Because TB-500 grips actin less tightly than the full-length protein, you will generally need higher concentrations to see the same response. Plan your dose ranges wider than you would for thymosin beta-4.
- Antibody detection will not work: Most commercial antibodies (lab detection tools) designed to find thymosin beta-4 target the sections that TB-500 is missing. They will not detect TB-500 at all. Use mass spectrometry or HPLC-based methods to measure it instead.
- Validate cell uptake separately: The smaller size of TB-500 may mean cells absorb it differently from the full-length protein. Confirm how much actually gets into your cell type before drawing conclusions from cell-based results.
Frequently Asked Questions About TB-500 Amino Acid Sequence and Structure
How many amino acids does TB-500 contain compared to thymosin beta-4?
TB-500 contains 17 amino acids, spanning a central segment of thymosin beta-4, which is a 43-residue protein. TB-500 retains the core actin-gripping region (the WH2-like motif) but omits the N-terminal SDKP starter piece and the C-terminal floppy tail.
Which specific residues in TB-500 are responsible for G-actin binding?
Published structural and mutagenesis data point to the LKKTET motif — roughly amino acids 17–22 of the parent thymosin beta-4 sequence — as the main actin-contact region. The two consecutive lysines (K18-K19) form key charge-based contacts with actin, while the leucine slips into a matching hydrophobic (water-repelling) groove on actin’s surface.
Does the shorter TB-500 sequence bind actin as strongly as full-length thymosin beta-4?
Not quite. Biophysical measurements in cell-free systems show that TB-500 does bind loose actin, but its grip is weaker than the full-length protein because it lacks the extra contact points from the flanking sections. In practical terms, you need more TB-500 to achieve the same saturation as less thymosin beta-4 in competition or binding assays.
Is there published structural data on the TB-500 fragment bound to actin?
Yes. Researchers have captured crystal structures — essentially molecular-level photographs — of thymosin beta-4 bound to actin, and the region covered by TB-500 is clearly visible in those images. The coordinate files are deposited in the Protein Data Bank, and you can find the relevant published papers by searching the PubMed database for thymosin beta-4 actin crystal structure.
For research use only. Not for human consumption. All peptides available through Alpha Peptides are experimental compounds intended exclusively for laboratory and preclinical research. Explore the full catalog at alpha-peptides.com/shop/ and review Certificates of Analysis.